Quarterly report [Sections 13 or 15(d)]

Fair Value Measurements - Financial Assets and Liabilities Carried at FV on Recurring Basis (Details)

v3.25.2
Fair Value Measurements - Financial Assets and Liabilities Carried at FV on Recurring Basis (Details) - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Assets:    
Exarafenib milestone asset (Note 4) $ 3,402 $ 3,214
Castle Creek warrants (Note 5) 609  
Liabilities:    
Exarafenib milestone contingent consideration (Note 4) 3,402 3,214
Fair Value, Recurring    
Assets:    
Cash equivalents 68,068 92,671
Investment in equity securities 8,801 3,529
Exarafenib milestone asset (Note 4) 3,402 3,214
Castle Creek warrants (Note 5) 609  
Total financial assets 80,880 99,414
Liabilities:    
Exarafenib milestone contingent consideration (Note 4) 3,402 3,214
Total financial liabilities 3,402 3,214
Fair Value, Recurring | Money market funds    
Assets:    
Cash equivalents 42,134 72,304
Fair Value, Recurring | U.S. treasury bills    
Assets:    
Cash equivalents 25,934 20,367
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets:    
Cash equivalents 68,068 92,671
Investment in equity securities 8,801 3,529
Total financial assets 76,869 96,200
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds    
Assets:    
Cash equivalents 42,134 72,304
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. treasury bills    
Assets:    
Cash equivalents 25,934 20,367
Fair Value, Recurring | Significant Unobservable Inputs (Level 3)    
Assets:    
Exarafenib milestone asset (Note 4) 3,402 3,214
Castle Creek warrants (Note 5) 609  
Total financial assets 4,011 3,214
Liabilities:    
Exarafenib milestone contingent consideration (Note 4) 3,402 3,214
Total financial liabilities $ 3,402 $ 3,214